Streetbeat News

BVNRY

Bavarian Nordic A/S

http://www.bavarian-nordic.com/

CEO

Paul Chaplin

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

Open

9.15

Mkt cap

2.2B

Volume

2.5K

High

9.19

P/E Ratio

13.50

52-wk high

14.60

Low

9.15

Div yield

N/A

52-wk low

7.89

The World Health Organization (WHO) has declared an international public health emergency over mpox due to a significant rise in cases, particularly in Africa. This has led to increased trading activity in stocks related to mpox vaccines and treatments, including Bavarian Nordic, Emergent Biosolutions, GeoVax Labs, and SIGA Technologies.

Portfolio Pulse from Chris Katje

August 14, 2024 | 8:58 pm

Bavarian Nordic's phase 3 chikungunya virus vaccine trial has hit its primary endpoint in healthy adults aged 65 and above. The company acquired the vaccine candidate from Emergent BioSolutions for $380 million and is competing with Valneva's VLA1553 vaccine.

Portfolio Pulse from Vandana Singh

June 20, 2023 | 6:30 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.